ArticleAnnals of hematology2026
Fixed-time treatment of elderly patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) using hypomethylating agents and venetoclax - a case series.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Standard therapy for elderly patients with acute myeloid leukemia (AML) consists of hypomethylating agents (HMAs) combined with venetoclax (VEN), administered long term until disease progression. However, several retrospective studies have shown that patients in complete remission (CR) who discontinued treatment electively or because of poor tolerance did not experience a negative impact on relapse-free or overall survival. Therefore, after obtaining informed consent, we offered treatment discontinuation to patients in CR after six months of HMA-VEN therapy. Here, we report the outcomes of seven consecutively treated patients who achieved CR between May 2021 and June 2025 and opted for discontinuation of therapy. Five of the seven patients showed clearance of somatic mutations to < 1% and resolution of cytogenetic abnormalities. Six of the seven patients remain in continuous remission for 7-50 months. One patient with FLT3-ITD experienced relapse after 14 months and achieved a second hematologic remission after resuming HMA-VEN therapy. These findings suggest that treatment-free remission after time-limited HMA-VEN therapy may be a feasible approach in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.